• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Tissue gene mutation profiles in patients with colorectal cancer and their clinical implications.结直肠癌患者的组织基因突变谱及其临床意义。
Biomed Rep. 2020 Jul;13(1):43-48. doi: 10.3892/br.2020.1303. Epub 2020 May 12.
2
Spatio-temporal mutation profiles of case-matched colorectal carcinomas and their metastases reveal unique de novo mutations in metachronous lung metastases by targeted next generation sequencing.病例匹配的结直肠癌及其转移灶的时空突变谱通过靶向二代测序揭示了异时性肺转移中独特的新发突变。
Mol Cancer. 2016 Oct 18;15(1):63. doi: 10.1186/s12943-016-0549-8.
3
Clinical significance of frequent somatic mutations detected by high-throughput targeted sequencing in archived colorectal cancer samples.高通量靶向测序在存档结直肠癌样本中检测到的常见体细胞突变的临床意义
J Transl Med. 2016 May 4;14(1):118. doi: 10.1186/s12967-016-0878-9.
4
Gene mutations in stool from gastric and colorectal neoplasia patients by next-generation sequencing.基于下一代测序的胃癌和结直肠癌患者粪便中的基因突变。
World J Gastroenterol. 2017 Dec 21;23(47):8291-8299. doi: 10.3748/wjg.v23.i47.8291.
5
Molecular spectrum of , , , , , and somatic gene mutations in Arab patients with colorectal cancer: determination of frequency and distribution pattern.阿拉伯结直肠癌患者中KRAS、NRAS、BRAF、PIK3CA、AKT1和FBXW7体细胞基因突变的分子谱:频率和分布模式的确定
J Gastrointest Oncol. 2016 Dec;7(6):882-902. doi: 10.21037/jgo.2016.11.02.
6
Construction of a multiplex mutation hot spot PCR panel: the first step towards colorectal cancer genotyping on the GS Junior platform.多重突变热点PCR检测板的构建:迈向GS Junior平台上结直肠癌基因分型的第一步。
J Cancer. 2017 Jan 12;8(2):162-173. doi: 10.7150/jca.16037. eCollection 2017.
7
Clinical significance of multiple gene detection with a 22-gene panel in formalin-fixed paraffin-embedded specimens of 207 colorectal cancer patients.207 例结直肠癌患者福尔马林固定石蜡包埋标本中 22 基因panel 多重基因检测的临床意义。
Int J Clin Oncol. 2019 Feb;24(2):141-152. doi: 10.1007/s10147-018-1377-1. Epub 2019 Jan 5.
8
Correlation between NGS panel-based mutation results and clinical information in colorectal cancer patients.基于二代测序(NGS)panel的结直肠癌患者突变结果与临床信息之间的相关性
Heliyon. 2024 Apr 5;10(7):e29299. doi: 10.1016/j.heliyon.2024.e29299. eCollection 2024 Apr 15.
9
Prevalence and coexistence of KRAS, BRAF, PIK3CA, NRAS, TP53, and APC mutations in Indian colorectal cancer patients: Next-generation sequencing-based cohort study.印度结直肠癌患者中KRAS、BRAF、PIK3CA、NRAS、TP53和APC基因突变的患病率及共存情况:基于二代测序的队列研究
Tumour Biol. 2017 Feb;39(2):1010428317692265. doi: 10.1177/1010428317692265.
10
Multigene Panel Sequencing Reveals Cancer-Specific and Common Somatic Mutations in Colorectal Cancer Patients: An Egyptian Experience.多基因检测揭示埃及结直肠癌患者的癌症特异性和常见体细胞突变
Curr Issues Mol Biol. 2022 Mar 18;44(3):1332-1352. doi: 10.3390/cimb44030090.

引用本文的文献

1
Computational screening of phytochemicals targeting mutant KRAS in colorectal cancer.针对结直肠癌中突变型KRAS的植物化学物质的计算筛选
Sci Rep. 2025 Aug 6;15(1):28754. doi: 10.1038/s41598-025-14229-z.
2
Crosstalk Between the Oncoproteins of High-Risk Human Papillomaviruses Types 16 and 18 in Colorectal Cancer Cell Models.高危型人乳头瘤病毒16型和18型癌蛋白在结直肠癌细胞模型中的相互作用
Cancer Rep (Hoboken). 2025 Jun;8(6):e70197. doi: 10.1002/cnr2.70197.
3
Molecular characterization of colorectal cancer (CRC) using next generation sequencing (NGS) in bridging the gap between research and clinical practice: from biomarker discovery to clinical implementation.利用下一代测序(NGS)对结直肠癌(CRC)进行分子特征分析,以弥合研究与临床实践之间的差距:从生物标志物发现到临床应用。
Discov Oncol. 2025 Mar 6;16(1):268. doi: 10.1007/s12672-025-01960-2.
4
Combining EGFR and KRAS G12C Inhibitors for KRAS G12C Mutated Advanced Colorectal Cancer.联合使用EGFR和KRAS G12C抑制剂治疗KRAS G12C突变的晚期结直肠癌
J Cancer Immunol (Wilmington). 2024;6(2):62-69. doi: 10.33696/cancerimmunol.6.086.
5
Targeted variant prevalence of FBXW7 gene mutation in colorectal carcinoma propagation. The first systematic review and meta-analysis.结直肠癌增殖中FBXW7基因突变的靶向变异患病率。首个系统评价与Meta分析。
Heliyon. 2024 May 22;10(11):e31471. doi: 10.1016/j.heliyon.2024.e31471. eCollection 2024 Jun 15.
6
Detecting colorectal cancer using genetic and epigenetic biomarkers: screening and diagnosis.利用遗传和表观遗传生物标志物检测结直肠癌:筛查和诊断。
J Med Life. 2024 Jan;17(1):4-14. doi: 10.25122/jml-2023-0269.
7
ATF6 supports lysosomal function in tumor cells to enable ER stress-activated macroautophagy and CMA: impact on mutant TP53 expression.ATF6 支持肿瘤细胞溶酶体功能,从而实现内质网应激激活的巨自噬和 CMA:对突变型 TP53 表达的影响。
Autophagy. 2024 Aug;20(8):1854-1867. doi: 10.1080/15548627.2024.2338577. Epub 2024 Apr 9.
8
The Role of KRAS Mutation in Colorectal Cancer-Associated Thrombosis.KRAS 突变在结直肠癌相关性血栓形成中的作用。
Int J Mol Sci. 2023 Nov 29;24(23):16930. doi: 10.3390/ijms242316930.
9
Murine models of colorectal cancer: the azoxymethane (AOM)/dextran sulfate sodium (DSS) model of colitis-associated cancer.结直肠癌的鼠类模型:葡聚糖硫酸钠(DSS)/氧化偶氮甲烷(AOM)诱导的结肠炎相关结肠癌模型。
PeerJ. 2023 Oct 31;11:e16159. doi: 10.7717/peerj.16159. eCollection 2023.
10
Canadian Consensus Recommendations on the Management of KRAS G12C-Mutated NSCLC.加拿大共识推荐意见:KRAS G12C 突变型 NSCLC 的管理
Curr Oncol. 2023 Jul 6;30(7):6473-6496. doi: 10.3390/curroncol30070476.

本文引用的文献

1
Targeted Therapy in Metastatic Colorectal Cancer: Current Standards and Novel Agents in Review.转移性结直肠癌的靶向治疗:当前标准与新型药物综述
Curr Colorectal Cancer Rep. 2019 Apr;15(2):61-69. doi: 10.1007/s11888-019-00430-6. Epub 2019 Mar 20.
2
Targeting the PI3K Signalling as a Therapeutic Strategy in Colorectal Cancer.以 PI3K 信号通路为靶点的结直肠癌治疗策略。
Adv Exp Med Biol. 2018;1110:35-53. doi: 10.1007/978-3-030-02771-1_4.
3
Next-generation sequencing-based clinical sequencing: toward precision medicine in solid tumors.基于新一代测序的临床测序:迈向实体瘤的精准医学。
Int J Clin Oncol. 2019 Feb;24(2):115-122. doi: 10.1007/s10147-018-1375-3. Epub 2018 Dec 4.
4
A meta-analysis of safety and efficacy of regorafenib for refractory metastatic colorectal cancer.瑞戈非尼用于难治性转移性结直肠癌安全性和有效性的荟萃分析。
Medicine (Baltimore). 2018 Oct;97(40):e12635. doi: 10.1097/MD.0000000000012635.
5
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.全球癌症统计数据 2018:GLOBOCAN 对全球 185 个国家/地区 36 种癌症的发病率和死亡率的估计。
CA Cancer J Clin. 2018 Nov;68(6):394-424. doi: 10.3322/caac.21492. Epub 2018 Sep 12.
6
The liquid biopsy in the management of colorectal cancer patients: Current applications and future scenarios.液体活检在结直肠癌患者管理中的应用:当前应用和未来前景。
Cancer Treat Rev. 2018 Nov;70:1-8. doi: 10.1016/j.ctrv.2018.07.007. Epub 2018 Jul 18.
7
Regorafenib: A Review in Metastatic Colorectal Cancer.regorafenib:转移性结直肠癌治疗的研究进展。
Drugs. 2018 Jul;78(11):1133-1144. doi: 10.1007/s40265-018-0938-y.
8
Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML.ivosidenib 治疗 IDH1 突变复发性或难治性 AML 的持久缓解。
N Engl J Med. 2018 Jun 21;378(25):2386-2398. doi: 10.1056/NEJMoa1716984. Epub 2018 Jun 2.
9
Performance validation of an amplicon-based targeted next-generation sequencing assay and mutation profiling of 648 Chinese colorectal cancer patients.基于扩增子的靶向下一代测序检测的性能验证及 648 例中国结直肠癌患者的突变分析。
Virchows Arch. 2018 Jun;472(6):959-968. doi: 10.1007/s00428-018-2359-4. Epub 2018 Apr 28.
10
Update on Hereditary Colorectal Cancer: Improving the Clinical Utility of Multigene Panel Testing.遗传性结直肠癌更新:提高多基因面板检测的临床实用性。
Clin Colorectal Cancer. 2018 Jun;17(2):e293-e305. doi: 10.1016/j.clcc.2018.01.001. Epub 2018 Jan 11.

结直肠癌患者的组织基因突变谱及其临床意义。

Tissue gene mutation profiles in patients with colorectal cancer and their clinical implications.

作者信息

Ye Jun, Lin Mei, Zhang Chuanmeng, Zhu Xiaowei, Li Sumeng, Liu Hui, Yin Jianfeng, Yu Hong, Zhu Kuichun

机构信息

Taizhou People's Hospital, The Center for Translational Medicine, Taizhou, Jiangsu 225300, P.R. China.

Xuzhou Medical University, Department of Pathology, Xuzhou, Jiangsu 221000, P.R. China.

出版信息

Biomed Rep. 2020 Jul;13(1):43-48. doi: 10.3892/br.2020.1303. Epub 2020 May 12.

DOI:10.3892/br.2020.1303
PMID:32440349
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7238404/
Abstract

Colorectal cancer (CRC) is one of the most common types of cancer in the world, and targeted therapy is frequently used in the clinical management of the disease. A complete and accurate picture of tissue gene mutations is therefore critical. Tissue specimens from 117 patients with CRC were used for high throughput DNA next-generation sequencing (NGS) analysis. Hotspots from 50 genes frequently associated with the development and progression of solid tumors were targeted for sequencing. Characterization of tissue gene mutations was performed; the tissue mutation positive rates of , , , and were 52.1, 19.7, 29.9, 15.4 and 14.5%, respectively. The mutation positive rates of , , , and were 65.8, 39.3, 32.5, 19.7 and 19.7%, respectively. The most frequent mutations were G12A/C/D/S/V, accounting for 61.2% of all mutations. The most frequent mutations were R273C/G/H/L, accounting for 8.5% of all mutations. The most frequent mutation was E1554fs, accounting for 19.7% of all mutations. R132C/H, M541L, N375S, and R361C/H were also frequently identified. mutations were more common in patients ≥60 years old (P<0.05), and mutations were more common in male patients (P<0.05). NGS 50 gene panel sequencing provides a comprehensive tissue gene mutation profile which may significantly improve clinical management.

摘要

结直肠癌(CRC)是世界上最常见的癌症类型之一,靶向治疗常用于该疾病的临床管理。因此,全面准确地了解组织基因突变情况至关重要。对117例CRC患者的组织标本进行了高通量DNA二代测序(NGS)分析。针对50个常与实体瘤发生和进展相关的基因热点进行测序。对组织基因突变进行了特征分析; 、 、 、 和 的组织突变阳性率分别为52.1%、19.7%、29.9%、15.4%和14.5%。 、 、 、 和 的突变阳性率分别为65.8%、39.3%、32.5%、19.7%和19.7%。最常见的 突变是G12A/C/D/S/V,占所有 突变的61.2%。最常见的 突变是R273C/G/H/L,占所有 突变的8.5%。最常见的 突变是E1554fs,占所有 突变的19.7%。还经常鉴定出R132C/H、M541L、N375S和R361C/H。 突变在60岁及以上患者中更常见(P<0.05), 突变在男性患者中更常见(P<0.05)。NGS 50基因panel测序提供了全面的组织基因突变谱,可能显著改善临床管理。